| Stereochemistry | ABSOLUTE |
| Molecular Formula | C27H22O18 |
| Molecular Weight | 634.4528 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O[C@H]1[C@@H]2COC(=O)C3=CC(O)=C(O)C(O)=C3C4=C(C=C(O)C(O)=C4O)C(=O)O[C@H]1[C@H](O)[C@@H](OC(=O)C5=CC(O)=C(O)C(O)=C5)O2
InChI
InChIKey=TUSDEZXZIZRFGC-VPIGZIKCSA-N
InChI=1S/C27H22O18/c28-9-1-6(2-10(29)16(9)32)24(39)45-27-22(38)23-19(35)13(43-27)5-42-25(40)7-3-11(30)17(33)20(36)14(7)15-8(26(41)44-23)4-12(31)18(34)21(15)37/h1-4,13,19,22-23,27-38H,5H2/t13-,19-,22-,23+,27+/m0/s1
| Molecular Formula | C27H22O18 |
| Molecular Weight | 634.4528 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Corilagin is a polyphenol, ellagitannin and hydrolyzable tannin that can be isolated from a variety of plants. This compound displays the ability to inhibit squalene epoxidase, a key enzyme in cholesterol synthesis, and NFκB pathway activation and also prevent the release of TNF-α at an IC50 of 76 μM. Additional studies show that Corilagin significantly inhibits type 1 plasminogen activator inhibitor (PAI-1) in rat plasma. Also has been reported to result in an increase in plasma tissue-type plasminogen activator (tPA) which results in the thrombolytic effect of Corilagin. In other studies, Corilagin showed some other pharmaceutical activities, such as antiviral effects in vitro, antinociceptive activity, anti-hyperalgesic activity, and action of anti-tumor in hepatocellular carcinoma and ovarian cancer.
Originator
Approval Year
PubMed
Sample Use Guides
Mice were treated with 20, 40, 80 mg/kg/day of Corilagin for consecutive four weeks
Route of Administration:
Oral